DK0896539T3 - Anvendelse af optisk rent (+)-norcisaprid til behandling af emesis og forstyrrelser i centralnervesystemet - Google Patents

Anvendelse af optisk rent (+)-norcisaprid til behandling af emesis og forstyrrelser i centralnervesystemet

Info

Publication number
DK0896539T3
DK0896539T3 DK97932467T DK97932467T DK0896539T3 DK 0896539 T3 DK0896539 T3 DK 0896539T3 DK 97932467 T DK97932467 T DK 97932467T DK 97932467 T DK97932467 T DK 97932467T DK 0896539 T3 DK0896539 T3 DK 0896539T3
Authority
DK
Denmark
Prior art keywords
norcisapride
treatment
nervous system
central nervous
optically pure
Prior art date
Application number
DK97932467T
Other languages
Danish (da)
English (en)
Inventor
John R Mccullough
Thomas P Jerussi
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Application granted granted Critical
Publication of DK0896539T3 publication Critical patent/DK0896539T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK97932467T 1996-07-19 1997-07-02 Anvendelse af optisk rent (+)-norcisaprid til behandling af emesis og forstyrrelser i centralnervesystemet DK0896539T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/684,753 US5739151A (en) 1996-07-19 1996-07-19 Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
PCT/US1997/011629 WO1998003173A1 (en) 1996-07-19 1997-07-02 Methods for treating emesis and central nervous system disorders using optically pure (+) norcisapride

Publications (1)

Publication Number Publication Date
DK0896539T3 true DK0896539T3 (da) 2001-02-19

Family

ID=24749413

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97932467T DK0896539T3 (da) 1996-07-19 1997-07-02 Anvendelse af optisk rent (+)-norcisaprid til behandling af emesis og forstyrrelser i centralnervesystemet

Country Status (25)

Country Link
US (3) US5739151A (xx)
EP (1) EP0896539B1 (xx)
JP (1) JP3097697B2 (xx)
KR (4) KR100328731B1 (xx)
CN (1) CN1215992A (xx)
AT (1) ATE197762T1 (xx)
AU (1) AU3592097A (xx)
BG (1) BG63190B1 (xx)
BR (1) BR9708287A (xx)
CA (1) CA2245768C (xx)
CZ (1) CZ293478B6 (xx)
DE (1) DE69703617T2 (xx)
DK (1) DK0896539T3 (xx)
ES (1) ES2152687T3 (xx)
GR (1) GR3035460T3 (xx)
HU (1) HUP9904360A3 (xx)
IL (1) IL125703A0 (xx)
IS (1) IS4820A (xx)
NO (2) NO317178B1 (xx)
NZ (1) NZ331291A (xx)
PL (1) PL189610B1 (xx)
PT (1) PT896539E (xx)
SK (1) SK282673B6 (xx)
TR (1) TR199801816T2 (xx)
WO (1) WO1998003173A1 (xx)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
US6147093A (en) 1996-07-19 2000-11-14 Sepracor Inc. Methods for treating gastroesophageal reflux disease
ES2180032T3 (es) * 1996-10-15 2003-02-01 Janssen Pharmaceutica Nv Procedimiento para preparar un compuesto intermedio util en la sintesis de cisaprida.
CN1196681C (zh) * 1997-07-11 2005-04-13 詹森药业有限公司 (+)诺西沙必利用于制备5－ht3和5ht4 介导的疾病的药物中的用途
EP1464333A3 (en) * 1998-06-15 2004-12-15 Sepracor Inc. Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders
EP1468685A3 (en) * 1998-06-15 2004-12-15 Sepracor Inc. Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders
ES2237117T3 (es) 1998-06-15 2005-07-16 Sepracor Inc. Uso de (-)norcisaprida opticamente pura en el tratamiento del sindrome del intestino irritable.
JP2002518352A (ja) * 1998-06-15 2002-06-25 セプラコア インコーポレーテッド 無呼吸、過食症およびその他の障害を治療するための光学的に純粋な（＋）−ノルシスアプリドの使用
ES2257869T3 (es) * 1998-08-21 2006-08-01 Novartis Ag Nueva formulacion oral para agonistas o antagonistas de 5-ht4.
US6362202B1 (en) * 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6353005B1 (en) * 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US6803387B1 (en) * 1999-03-19 2004-10-12 Abbott Gmbh & Co. Kg Treatment of neuropathic pain or fibromyalgia
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
EP1321142A1 (en) * 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
FR2854072B1 (fr) * 2003-04-23 2006-08-04 Centre Nat Rech Scient Vecteur pour administration par voie orale
US8138204B2 (en) * 2004-01-07 2012-03-20 Aryx Therapeutics, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US8524736B2 (en) 2004-01-07 2013-09-03 Armetheon, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
DK2194053T3 (da) 2004-01-07 2013-07-01 Armetheon Inc Methoxypiperidinderivater til brug i behandling af gastrointestinale forstyrrelser og forstyrrelser i centralnervesystemet.
US20090170899A1 (en) * 2004-09-14 2009-07-02 Guy Debonnel Stimulators of 5-HT4 receptors and uses thereof
KR101351454B1 (ko) * 2005-08-31 2014-01-14 아메데온, 인코포레이티드 위장 및 중추 신경계 장애의 치료에 유용한 입체이성질체 화합물의 합성 방법 및 중간 생성물
US20080085915A1 (en) * 2006-06-23 2008-04-10 Cyrus Becker Compounds and methods for the treatment of gastrointestinal and central nervous system disorders
EP2488171A4 (en) 2009-10-16 2014-04-23 Epiomed Therapeutics Inc TREATMENT OF VOMITING
WO2012115478A2 (en) * 2011-02-25 2012-08-30 Yuhan Corporation Diaminopyrimidine derivatives and processes for the preparation thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962115A (en) * 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
CA1183847A (en) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5057525A (en) * 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
US5137896A (en) * 1981-10-01 1992-08-11 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5114714A (en) * 1990-11-29 1992-05-19 Sepracor, Inc. Methods of use and compositions of (r)-isoflurane and (r)-desflurane
US5114715A (en) * 1990-11-29 1992-05-19 Sepracor Inc. Methods of use and compositions of (s)-isoflurane and (s)-desflurane
CA2139638A1 (en) * 1992-07-07 1994-01-20 Nancy M. Gray Methods of using (-) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
AU4770593A (en) * 1992-07-07 1994-01-31 Sepracor, Inc. Methods of using (+) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
JPH08512322A (ja) * 1993-07-06 1996-12-24 メルク エンド カンパニー インコーポレーテッド Ｈ▲下２▼拮抗剤−胃腸運動性の薬剤組合せ物
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride

Also Published As

Publication number Publication date
NO983636D0 (no) 1998-08-07
HUP9904360A3 (en) 2001-07-30
KR20040007505A (ko) 2004-01-24
TR199801816T2 (xx) 2000-10-23
KR100422492B1 (ko) 2004-03-11
JPH11510828A (ja) 1999-09-21
HUP9904360A2 (hu) 2000-05-28
CZ293478B6 (cs) 2004-05-12
DE69703617D1 (de) 2001-01-04
WO1998003173A1 (en) 1998-01-29
PT896539E (pt) 2001-05-31
KR100533237B1 (ko) 2005-12-05
PL335254A1 (en) 2000-04-10
BR9708287A (pt) 2000-01-18
DE69703617T2 (de) 2001-04-12
SK282673B6 (sk) 2002-11-06
ES2152687T3 (es) 2001-02-01
PL189610B1 (pl) 2005-08-31
BG63190B1 (bg) 2001-06-29
CA2245768A1 (en) 1998-01-29
NZ331291A (en) 2000-06-23
KR100328731B1 (ko) 2002-10-19
AU3592097A (en) 1998-02-10
EP0896539A1 (en) 1999-02-17
JP3097697B2 (ja) 2000-10-10
IS4820A (is) 1998-08-10
GR3035460T3 (en) 2001-05-31
BG102757A (en) 1999-08-31
CA2245768C (en) 2003-09-30
IL125703A0 (en) 1999-04-11
US5877188A (en) 1999-03-02
SK123998A3 (en) 1999-03-12
US6114356A (en) 2000-09-05
CZ250898A3 (cs) 1999-04-14
NO317178B1 (no) 2004-09-06
NO20041166L (no) 2004-03-19
NO983636L (no) 1998-10-19
KR100399808B1 (ko) 2003-09-29
KR20000064524A (ko) 2000-11-06
CN1215992A (zh) 1999-05-05
ATE197762T1 (de) 2000-12-15
EP0896539B1 (en) 2000-11-29
US5739151A (en) 1998-04-14

Similar Documents

Publication Publication Date Title
DK0896539T3 (da) Anvendelse af optisk rent (+)-norcisaprid til behandling af emesis og forstyrrelser i centralnervesystemet
ATE203019T1 (de) Neue (r)-5-carbamoyl-8-fluor-3-n,n- disubstituierte-amino-3,4-dihydro-2h-1- benzopyrane
ATE194593T1 (de) 3-(3,4-dioxyphenyl)-pyrrolidine als inhibitonen der typ iv - phosphodiesterase zur behandlung von entzündungskrankheiten
NO991685D0 (no) Anvendelse av 1-benzyl-3-(substituert hetaryl)-kondenserte pyrazolderivater for behandling av spesielle sykdommer i hjerte-kretsl°psystemet og sentralnervesystemet
YU70294A (sh) Kristalni hidranti derivati 3,4,4-trisupstituisanih-piperidinil-n-alkilkarbok silata, njihovi intermedijari i postupak za dobijanje
YU37696A (sh) Postupak optičkog prečišćavanja jedinjenja
DK2018874T3 (da) Farmaceutiske sammensætninger til forebyggelse og behandling af lidelser i centralnervesystemet indeholdende en nikotinisk agonist og en acetylcholinesteraseinhibitor
DK0740650T3 (da) Codrugs som metode til styret transport af lægemiddel
DK0831821T3 (da) Optisk rent (-)-norcisaprid til behandling af forstyrrelser i fordöjelseskanalen
DK1311256T3 (da) Anvendelse af derivater af valproinsyreamider og 2-valproinsyreamider til behandling eller forebyggelse af smerter og/eller hovedpinelidelser
AU3401797A (en) Compounds having effects on serotonin-related systems
NO965516L (no) Sterolderivater anvendt til regulering av meiose
DK0556332T3 (da) Substituerede tetrahydropyridiner og hydroxypiperidiner som midler til behandling af centralnervesystemet
ES2188984T3 (es) Procedimiento de enriquecimiento en r de epimeros de derivados de 16,17-acetales de derivados de 21-aciloxi-pregnano-1,4-dieno-11-beta, 16alfa-triol-3,20-dionas.
DK1000029T3 (da) Norcisaprid nyttig med hensyn til 5-HT3- og 5-HT4- medierede lidelser
PA8457001A1 (es) Derivados del 2-(4-aril o heteroaril-piperazin-i-ilmetil)-1h-indol
DK0700384T3 (da) fremgangsmåde til fremstilling og opløsning af 2-phenyl-3-aminopiperidin
DK1124556T3 (da) Anvendelse af optisk rent (R)-tofisopam til behandling og forebyggelse af angstsygdomme
MXPA02000330A (es) Pirrolidinas y piperidinas neurotroficas y composiciones y metodos relacionados.
DE69928375D1 (de) Analgetikum aus schlangengift
DK0996435T3 (da) Aminosyrederivater anvendelige til behandling af slagtilfælde
BG105218A (en) The use of optically pure (+) norcisapride for treating gastro-esophageal reflux disease
DK0656209T3 (da) Melatoninderivater til anvendelse ved behandling af desynkroniseringsforstyrrelser
PL310950A1 (en) Novel imidazole quinoxalinones, method of obtaining them and their application
DK0935598T3 (da) 5-heteroatom-alkylsubstituerede 3-oxopyrido(1,2-a)benzimidazol-4-carboxamidderivater egnede til behandling af sygdomme i centralnervesystemet